Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 7, 2026

Robinhood Markets and Starbucks have been highlighted as Zacks Bull and Bear of the Day

View original at finance.yahoo.com
Robinhood Markets and Starbucks have been highlighted as Zacks Bull and Bear of the Day For Immediate Release Chicago, IL – January 7, 2026 – Zacks Equity Research shares Robinhood Markets HOOD, as the Bull of the Day and Starbucks SBUX as the Bear of the Day…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The top 5% of all stocks receive the highly coveted Zacks Rank #1 (Strong Buy). These stocks should outperform the market more than any other rank.

    80% confidence

  • Robinhood Markets sports the highly-coveted Zacks Rank #1 (Strong Buy), with its EPS outlook remaining rosy

    80% confidence

  • The revised net sales guidance reflects a broad-based recovery in most of Microchip's end markets, driven by improving inventory conditions at distributors as well as direct customers. The company saw strong bookings in December and expects further improvement in the March quarter.

    80% confidence

  • Starbucks has Zacks Rank #5 (Strong Sell) due to analysts taking earnings expectations lower

    80% confidence

  • Since 2000, top stock-picking strategies have blown away the S&P's +7.7% average gain per year with average gains of +48.4%, +50.2% and +56.7% per year

    80% confidence

  • Q4 was a milestone quarter in getting 'Back to Starbucks', having delivered global comp growth for the first time in seven quarters. This continues to be a multi-year turnaround. The company remains focused on driving topline while managing costs to deliver durable, sustainable growth and long-term shareholder value.

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
Robinhood Markets and Starbucks have been highlighted as Zacks Bull and Bear of the Day — Source | Via News | ViaNews EU